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Abstract
Introduction: The first few months after symptom onset represents a pathologically distinct phase in rheumatoid 
arthritis (RA). We used relevant experimental models to define the pathological role of interferon-γ (IFN-γ) during early 
inflammatory arthritis.
Methods: We studied IFN-γ's capacity to modulate interleukin-1β (IL-1β) induced degenerative responses using RA 
fibroblast-like synoviocytes (FLS), a bovine articular cartilage explant (BACE)/RA-FLS co-culture model and an 
experimental inflammatory arthritis model (murine antigen-induced arthritis (AIA)).
Results: IFN-γ modulated IL-1β driven matrix metalloproteinases (MMP) synthesis resulting in the down-regulation of 
MMP-1 and MMP-3 production in vitro. IFN-γ did not affect IL-1β induced tissue inhibitor of metalloproteinase-1 (TIMP-
1) production by RA FLS but skewed the MMP/TIMP-1 balance sufficiently to attenuate glycosaminoglycan-depletion 
in our BACE model. IFN-γ reduced IL-1β expression in the arthritic joint and prevented cartilage degeneration on Day 3 
of AIA.
Conclusions: Early therapeutic intervention with IFN-γ may be critical to orchestrate tissue-protective responses 
during inflammatory arthritis.
Introduction
Interferon-γ (IFN-γ) is traditionally regarded as a proin-
flammatory cytokine by virtue of its strong macrophage-
activating potential and its association with Th1 driven
immune responses. This view is predominantly derived
from in vitro observations at the cellular level. This belief
has no doubt also contributed to our over-simplified
understanding of major human autoimmune disorders
such as rheumatoid arthritis (RA), multiple sclerosis and
insulin-dependent diabetes mellitus and guided the
development of therapeutic strategies for these diseases
for over two decades. Accumulating contradictory find-
ings from several in vivo experimental models of disease
[1-7] as well as the suppressive role of IFN-γ upon inter-
leukin-17 [8] signifies a need to rethink the doctrine of
proinflammatory and disease-enforcing function for IFN-
γ in autoimmune diseases such as RA.
The strong protective role for IFN-γ is exemplified in
experimental models of arthritis, whereby genetic disrup-
tion of the IFN-γ receptor or IFN-γ results in increased
disease activity [5-7]. In humans also a key immuno-
modulatory function for IFN-γ may be postulated in very
early arthritis. Raza et al demonstrated that patients pre-
senting with inflammatory joint pain, joint related soft
tissue swelling or early morning stiffness or a combina-
tion thereof for approximately three months displayed a
distinct, but transient, synovial cytokine profile [9]. In the
cohort of patients who went on to developed RA, a broad
range of T-cell, macrophage and stromal cell related
cytokines were elevated in synovial fluid samples; how-
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Page 2 of 10ever, IFN-γ was never detected. If the cytokines present
in the early rheumatoid lesion define the microenviron-
ment which is required for RA pathology then, based
upon current data from mice and humans, IFN-γ may
prove to be a potentially important disease-modifying
cytokine. The role of IFN-γ during the early phase of
inflammatory arthritis has not been extensively studied.
In RA the first few months after symptom onset repre-
sents a pathologically distinct phase of disease which may
translate into a therapeutic window and crucial target for
implementing aggressive treatment protocols to perma-
nently switch off or significantly arrest the disease pro-
cess [9-11]. Detailed mechanistic information relating to
the earliest stages of RA is limited by several contributory
factors: (i) the changing clinical definition of early RA
[12], (ii) access to sensitive imaging tools to detect early
joint damage, (iii) traditional use of radiographic evalua-
tion of bone erosion to quantify destructive pathology,
(iv) cartilage degeneration (the earliest sign of joint dam-
age in RA) is inherently problematic to visualise. Conse-
quently, the role of IFN-γ in modulating articular
cartilage during early RA has not been investigated previ-
ously.
The synovial membrane, recognised as the primary
pathogenic site in RA, has been particularly informative
in the study of novel therapeutic agents. Fibroblast-like
synoviocytes (FLS), the major cellular constituent of the
synovial membrane, are the main contributors to carti-
lage-degrading matrix metalloproteinase (MMP) over-
production within the arthritic joint [13-15]. We used
FLS cultured from RA synovial tissue specimens to
model inflammation-induced MMP production and car-
tilage degeneration during the aetiopathogenesis of RA.
Experimental data presented in this article, demonstrate
an important regulatory function of IFN-γ in modulating
FLS responses to IL-1β, specifically their ability to pro-
duce MMP-1 and MMP-3. This aspect of IFN-γ's func-
tionality has not previously been reported. The balance
between the bioactivities of MMPs and their inhibitors in
the local tissue environment is a likely determinant of
cartilage extracellular matrix degradation. We used
bovine articular cartilage explants (BACE) to examine the
biological activity of IL-1β activated RA FLS. Our results
demonstrate the capacity of IL-1β activated RA FLS to
degrade intact cartilage matrix and that IFN-γ potently
protects articular cartilage against IL-1β induced damage
ex vivo. In order to replicate the complexity of cellular
and molecular interactions which regulate early cartilage
injury in RA we utilised the well-published antigen-
induced arthritis (AIA) model of inflammatory arthritis.
Our data support a key protective role for IFN-γ signal-
ling in limiting cartilage deterioration in early inflamma-
tory arthritis; an outcome directed by IFN-γ's capacity to
modulate the synovial expression of IL-1β and attenuate
IL-1β-induced MMP production by FLS.
Materials and methods
Preparation and analysis of FLS
Human synovium was obtained from 13 consenting
patients with RA who underwent synovectomy at the
time of joint replacement (eight elbow replacements, and
five knee replacements). At the time of joint replacement
the mean age was 66 (range 46 to 77). Samples were
obtained from nine females and four males; all patients
had disease duration of greater than eight years. None of
the patients had received anti-TNF therapy prior to sur-
gery. Ethical approval for the study was obtained from
Bro-Taf Health Authority (Reference 02/4692-Cardiff,
Wales, UK). RA FLS were harvested and maintained in
culture as previously described [7]. Briefly, RA FLS were
harvested after collagenase digestion and expanded in
culture flasks containing Dulbecco's modified Eagle's
medium and Ham's F-12, at a 1:1 ratio, supplemented
with 10% bovine fetal calf serum, antibiotics, L-glu-
tamine, insulin and transferrin (DMEM/F12) (Life Tech-
nologies Invitrogen, Paisley, UK). RA FLS (n = 10) were
used exclusively at the fourth passage. Experiments were
performed in duplicate. RA FLS were stimulated with
either recombinant human IL-1β (0.1 ng/ml), IFN-γ (0 to
10 ng/ml) or IL-1β in combination with escalating con-
centrations of IFN-γ (R&D Systems, Abingdon, UK).
Control wells were incubated in DMEM/F12 only. Super-
natants were harvested over a 72-hour timecourse and
stored at -70°C prior to analysis. Cell viability was
assessed by Alamar Blue Assay performed according to
the manufacture's guidelines (Biosource International,
Camarillo, California, USA) and was found to be greater
than 95% at all time points.
Ex vivo bovine articular cartilage explant (BACE) model
At fourth passage RA FLS (7.5 × 104/well) were dispensed
into a 12 well plate (NUNC™, Fisher Scientific, Loughbor-
ough, UK). Cells were grown until 90% confluent, nor-
mally within three days of passage. Full depth BACE were
obtained from the metacarpal-phalangeal joint of imma-
ture (seven day old) bovine limbs using a published meth-
odology [16]. Explants were maintained in DMEM/F12
for 24 hours at 37°C in a humidified incubator (5% CO2/
air) prior to experimentation. Two plates were set up in
parallel for each experiment, each condition was tested in
duplicate and three RA-FLS cell lines were examined in
all. On Plate 1: one BACE was dispensed into each of a
12-well plate. On Plate 2: one BACE was added to each
well of a 12-well plate containing RA FLS. The BACE
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bated for 72 hours with either DMEM/F12 or DMEM/
F12 containing 0.1 ng/ml IL-1β, 10 ng/ml IFN-γ or the
two cytokines in combination at the concentration speci-
fied. At end-point, supernatants were collected and
stored at -70°C prior to analysis for MMP-3. BACE were
also reserved, fixed in 10% neutral buffered formal saline,
processed and then embedded in paraffin wax prior to
histological evaluation. Proteoglycan depletion in fixed
BACE was measured after Safranin-O/fast green staining.
Enzyme-linked immunosorbant assay (ELISA)
Matched antibody pairs and protein standards for use in
MMP-1 ELISA were obtained from R&D Systems (R&D
Systems Europe, Ltd. Abingdon, UK). MMP-3 was mea-
sured using the specific human BioSource CytoSet™
CHC1544 ELISA kit (Life Technologies Corporation,
Carlsbad, California, USA), MMP-13 using the human
Quantikine® DM1300 ELISA kit (R&D Systems Europe,
Ltd. Abingdon, U.K) and TIMP-1 using the human Duo-
Set® DY970 ELISA kit (R&D Systems Europe, Ltd. Abing-
don, U.K).
Plasma cytokines (IL-1β and IFN-γ) were measured
using mouse specific Quantikine® Immunoassays (R&D
Systems Europe, Ltd. Abingdon, UK). Assays were per-
formed in accordance with the manufacturer's instruc-
tions.
Mouse strains
Inbred wild-type (WT) BALB/c mice (IFN-γ+/+) were
purchased from Charles River UK (Margate, UK). IFN-γ-
deficient (IFN-γ-/-) mice on the BALB/c background
were bred in house from breeding pairs provided by Pro-
fessor Casey T Weaver (University of Alabama at Bir-
mingham, AL, USA). All mice were maintained under
barrier conditions and were pathogen free as assessed by
regular microbiologic screening.
Induction and assessment of murine AIA
Experiments were performed in seven- to eight-week-old
male mice. Experimental procedures were performed in
accordance with UK Home Office Project License PPL-
30/1820 and 30/2361. For statistical analysis, a minimum
of six animals per group were used; all experiments were
duplicated to assure reproducibility of response. AIA was
induced according to reported methodology [7,17].
Briefly, mice were immunized twice (one week apart)
with an emulsion containing 1 mg/ml methylated bovine
serum (mBSA) in complete Freund's adjuvant. Heat-inac-
tivated Bordetella pertussis toxin was injected intraperi-
toneally as a non-specific immune activator (all reagents
were from Sigma, Poole, UK). Twenty-one days after the
initial immunization, arthritis was induced after an intra-
articular (i.a.) injection of mBSA in PBS (0.1 μg/joint)
into the right knee (stifle) joint.
Animals were evaluated daily for three days following
i.a. mBSA injection. Arthritis was assessed by measuring
knee joint diameters using a digital micrometer. The dif-
ference in joint diameter between the arthritic (right) and
non-arthritic control (left) stifle joints in each animal
gave a quantitative measure of swelling (in mm).
Histologic assessment
Animals were sacrificed three days after i.a. mBSA injec-
tion. Knee joints were dissected, fixed in 10% neutral
buffered formal saline, and decalcified with formic acid at
4°C prior to embedding in paraffin. Mid-sagittal serial
sections (5 μm thickness) were cut and stained with hae-
matoxylin and eosin (H&E) for visualising gross pathol-
ogy or Safranin O-fast green staining for
glycosaminoglycan (GAG) [18].
Disease severity was graded histologically by two
blinded observers using defined disease activity parame-
ters. Synovial hyperplasia (pannus formation) and cellular
exudate were each scored from 0 (normal) to 3 (severe)
whilst the synovial infiltrate was scored from 0 to 5. All
parameters were subsequently summed to give an arthri-
tis index (AI; expressed as the Mean ± SEM).
Cartilage depth and GAG depletion was measured
(μm) in five random fields on the femoral articular sur-
face. These areas were remote from the inflamed syn-
ovium.
Immunohistochemistry
Paraffin wax-embedded knee sections were prepared and
stained as previously described. Briefly, sections were
treated with trypsin (0.1% w/v). Endogenous peroxidase
and biotin were blocked using Chem-Mate Peroxidase
blocking solution and biotin-blocking system respectively
(Dako, Ely, UK). Sections were stained with rabbit anti-
mouse IL-1β (1:50; Santa Cruz Biotechnology, Santa
Cruz, CA, USA), and antibody binding was detected
using the appropriate biotin-conjugated secondary anti-
body followed by StreptABComplex (Dako, Ely, UK).
Control slides were probed with naive rabbit IgG and
processed as above. Sections were developed using
diaminobenzidine substrate and counterstained with
haematoxylin.
Statistical analysis
Tukey's test was used in conjunction with a one-way anal-
ysis of variance to analyze differences in cytokine and
protease levels measured by ELISA. In AIA knee swelling
was evaluated daily for three days following i.a. mBSA
injection. Statistical analysis was performed using
unpaired one-way analysis of variance. Disease severity in
these animals was graded histologically using defined dis-
ease activity parameters. The Mann-Whitney U test was
used to analyze differences between WT and IFN-γ-/-
mice. Quantitative differences in GAG depletion (ex vivo
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ance. P values less than 0.05 were considered statistically
significant. Values are expressed as the mean ± SEM.
Results
IFN-γ inhibits IL-1β induced MMP secretion by RA FLS
In RA cartilage damage is predominantly mediated by the
MMPs; most notably MMP-1, -13 and -3 [19]. Their syn-
thesis is driven by pro-inflammatory cytokines, most par-
ticularly IL-1 [20]. Collectively these MMPs degrade the
major components of the extracellular matrix in cartilage
and in bone. They are predominantly synthesised by both
macrophages and FLS in the hyperplasic synovium. We
studied IFN-γ's capacity to modulate IL-1β-induced
MMP production by RA FLS.
IFN-γ did not induce significant MMP-1 nor did it
induce significant MMP-3 production (mean ± SEM, ng/
ml) in RA FLS over 72 hours (IFN-γ (10 ng/ml) versus
control media at 72 hrs; MMP-1 = 15 ± 6 vs. 9.5 ± 3 and
MMP-3 = 3.7 ± 1.7 vs. 3.1 vs. 1.4). In contrast MMP-1 and
MMP-3 expression increased in RA FLS in response to
IL-1β activation (0.1 ng/ml) for periods up to 72 hours
(Figure 1). Co-administration of IL-1β with increasing
concentrations of IFN-γ resulted in a significant reduc-
tion in detectable MMP-1 and MMP-3 levels when com-
pared to that elicited by the IL-1β alone (Figure 1).
By virtue of its capacity to metabolise type II collagen
over interstitial type I and III collagens, MMP-13 is also
implicated in the degradation of extracellular matrix
within articular cartilage. In our studies we observed
maximal MMP-13 production (mean ± SEM) in RA FLS
24 hours after stimulation with IL-1β (1.0 ± 0.3 ng/ml);
which plateaued between 48 and 72 hours (0.8 ± 0.3 ng/
ml). Co-stimulation with IFN-γ reduced MMP-13 secre-
tion to 0.8 ± 0.1 ng/ml and 0.4 ± 0.08 ng/ml at 24 and 72
hours respectively. This reduction in MMP-13 produc-
tion was not statistically significant. Of note, however, RA
FLS secreted >100 fold more MMP-1 than MMP-13
under the same in vitro conditions, implying that perhaps
production of MMP-1 by FLS is more important than
that of MMP-13 in catalysing cartilage degradation in
RA. IFN-γ is therefore able to negatively regulate patho-
logical MMP secretion by RA FLS in a pro-inflammatory
setting.
IFN-γ does not affect tissue protective TIMP-1 secretion by 
RA FLS
The enzymatic activity of the MMPs is strictly regulated
by specific inhibitors, the tissue inhibitors of metallopro-
teinases family (TIMP). Since synovial lining cells in RA
specifically overproduce TIMP-1 [19,21], the effect of
IFN-γ on the generation of this important regulator of
cartilage and extracellular matrix degradation was deter-
mined. RA FLS constitutively produced high levels of
TIMP-1 in culture media without cytokine activation
(Figure 2A). IFN-γ treatment only marginally increased
TIMP-1 secretion (P = NS). Incubation of RA FLS with
IL-1β for 72 hours resulted in a time dependent increase
in the secreted levels of TIMP-1. Co-administration of
IL-1β with concentrations of IFN-γ up to 10 ng/ml did
not significantly alter TIMP-1 generation (Figure 2B).
IFN-γ protects articular cartilage from IL-1β induced GAG 
depletion
The balance between the bioactivities of MMPs and
TIMPs in the local tissue environment is a likely determi-
nant of cartilage extracellular matrix degradation. We
therefore examined whether the sum of the biological
activities of MMP/TIMP generated by IL-1β activated RA
FLS was sufficiently skewed as to induce GAG depletion
in a BACE model. After 72 hours in culture we noted
diminutive reductions in Safranin-O/fast green staining
Figure 1 IFN-γ inhibits IL-1β induced MMP-1 and MMP-3 produc-
tion by RA FLS in vitro. Fibroblast-like synoviocytes (FLS) were isolat-
ed from rheumatoid arthritis (RA) synovial tissue specimens. Ten RA 
FLS cell lines were studied in all. At fourth passage RA FLS were incu-
bated with either culture medium, IL-1β (0.1 ng/ml), escalating doses 
of IFN-γ (0.1 to 10 ng/ml) or combinations of the two cytokines for 72 
hours. Culture supernatants were harvested at 24, 48 and 72 hours. 
Protease concentrations were measured by ELISA; (A) MMP-1 and (B) 
MMP-3 (mean ± SEM) values are reported. Tukey's test was used in 
conjunction with a one-way analysis of variance to analyze differences 
in protease levels. P values less than 0.05 were considered statistically 
significant; * P < 0.05, **P < 0.01 and ***P < 0.001.
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Page 5 of 10in BACE incubated in DMEM/F12 or medium containing
IL-1β IFN-γ or the two cytokines in combination (Figure
3A-C). GAG depletion, which penetrated the BACE by
approximately 25 μm, was comparable in all BACE test
culture conditions. This basal GAG depletion was attrib-
uted to our choice of media which was optimised for FLS
rather than chondrocyte culture.
Three RA FLS cell lines were tested in all. In each case
extensive GAG depletion (mean ± SEM) was observed in
IL-1β activated BACE/RA FLS co-cultures (64 ± 7 μm,
Figure 3D, G). This FLS dependent GAG depletion was
significantly greater than the GAG depletion measured in
BACE in the absence of RA FLS (29.7 ± 4.8 μm, Figure
3A; P < 0.001). Co-administration of IFN-γ potently pro-
tected the BACE from GAG depletion induced by IL-1β-
activated RA FLS (36.2 ± 5.5 μm, Figure 3G); evidenced
by the intense red staining for Safranin O (Figure 3F).
Figure 2 IFN-γ does not affect tissue protective TIMP-1 secretion 
by RA FLS in vitro. Fibroblast-like synoviocytes (FLS) were cultured 
from synovial tissue specimens obtained from rheumatoid arthritis 
(RA) patients at synovectomy or joint replacement. Eight cell lines were 
used at fourth passage. Cells were incubated in culture medium or in 
medium containing escalating doses of IFN-γ (0.1 to 10 ng/ml), IL-1β 
(0.1 ng/ml) or combinations of the two cytokines for 72 hours. TIMP-1 
levels were quantified by ELISA in culture supernatants at 24, 48 and 72 
hours; mean ± SEM TIMP-1 concentrations are reported. (A) TIMP-1 lev-
els were significantly increased by IL-1β but not escalating concentra-
tions of IFN-γ. IFN-γ did not affect IL-1β induced TIMP-1 production by 
RA FLS; (B) represents data obtained for 10 ng/ml IFN-γ ± IL-1β (0.1 ng/
ml). Tukey's test was used in conjunction with a one-way analysis of 
variance to analyze differences in TIMP-1 levels. P values less than 0.05 
were considered statistically significant. NS denotes non-significant 
change, *P < 0.05 and **P < 0.005.
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Figure 3 IFN-γ protects articular cartilage from GAG depletion 
mediated by IL-1β activated RA FLS ex vivo. Full depth articular car-
tilage explants were obtained from bovine limbs (BACE). Two 12-well 
plates were set up in parallel, one with RA FLS the second without RA 
FLS. At the beginning of each experiment, one BACE was place in each 
well. BACE (± RA FLS) were incubated in DMEM/F12 or medium con-
taining; 0.1 ng/ml IL-1β, 10 ng/ml IFN-γ or IL-1β with IFN-γ for 72 hours 
when cartilage explants and supernatants were reserved. Three RA FLS 
cell lines were tested; cytokines (alone or in combination) were exam-
ined in duplicate. Cartilage depletion at end point was visualised in Sa-
franin-O/Fast Green-stained sections. Representative images from one 
experiment are reported (A-F), reduced intensity of red stain denotes 
proteoglycan loss (original magnification × 20). A-C BACE cultured 
without RA FLS, D-E corresponding BACE from RA FLS co-cultures 
which had been incubated in DMEM/F12 medium containing: 0.1 ng/
ml IL-1β (A and D), 10 ng/ml IFN-γ (B and E) or IL-1β with IFN-γ (C and 
F) for 72 hours. The depth of GAG depletion (μm) in each BACE, mea-
sured from the articular surface to the red/orange tidemark (denoted 
by black block arrow) is presented graphically in (G); mean ± SEM for 
three experiments reported. MMP-3 was measured by ELISA in culture 
supernatants harvested from each well after 72 hours in culture. (H) 
MMP-3 (ng/ml); mean ± SEM for three experiments. One-way analysis 
of variance was used to analyze differences in GAG depletion and 
MMP-3 levels: *P < 0.05 and **P < 0.0001.
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ular cartilage by modulating IL-1β induced RA FLS pro-
tease production we measured MMP-3 levels in
supernatant at the 72-hour endpoint for our experiments.
Consistent with our finding in RA FLS monocultures, we
found that BACE/RA FLS co-cultures produced negligi-
ble MMP-3 in response to IFN-γ activation (3.1 ± 1.0 ng/
ml). Co-administration of IL-1β with IFN-γ resulted in a
significant reduction in detectable MMP-3 levels when
compared to that elicited by IL-1β alone (Figure 3H). Our
data imply that IFN-γ safeguards articular cartilage by
modulating IL-1β induced protease production by RA
FLS.
Joint pathology in IFN-γ-deficient mice with early AIA
Comparison of the histopathology of synovial tissue dur-
ing early RA, established RA, and in non-RA synovitis
has shown subtle, but potentially important differences in
histologic features, cytokine and protease expression pat-
terns [22,23]. The histopathology of the early RA demon-
strates mild proliferation of synovial lining cells, an
abundant occurrence of mononuclear phagocytes (sub-
lining layer) and a diffuse T cell infiltrate (subsynovial
layer) [24]. Similar characteristic pathological features are
evident in AIA during the acute phase, up to three days
after arthritis induction [7,25,26]. We therefore elected to
run our in vivo experiments for three days; a period of
time which we felt best represented very early RA.
Wild type (IFN-γ+/+) and IFN-deficient (IFN-γ-/-)
mice were both highly susceptible to the development of
AIA. One day after intra-articular (i.a.) administration of
methylated bovine serum albumin (mBSA) we detected
small but significant (P < 0.05) increases in plasma levels
of IL-1β in IFN-γ-/- mice (13.4 ± 1.1 pg/ml vs. 8.7 ± 1.3
pg/ml for WT). IFN-γ levels were only detectable in WT
mice (36.8 ± 0.4 pg/ml) (Figure 4A). IL-1β nor IFN-γ were
detectable in plasma samples at subsequent time points
(Day 2 and Day 3). We observed moderate IL-1β expres-
sion in joints affected by AIA on Day 1. Abundant stain-
ing was detected in the synovial lining layer, joint exudate
and focal areas of synovial infiltration; it was comparable
in WT and IFN-γ-/- mice (Figures 4B, C). Histological
evaluation of joint tissue specimens demonstrated that all
inflammatory parameters were equivalent; this was
reflected in the Arthritis Index (AI) which was not signif-
icantly different in WT and IFN-γ-/-; 6.4 ± 0.4 vs. 7.0 ±
0.6 (Figure 4D). There was no evidence of cartilage deple-
tion by Safranin-O/fast green staining despite the dis-
cernible inflammatory synovial environment (Figure 4E-
H).
IFN-γ protects the joint against early articular cartilage 
damage in AIA
By Day 3 all parameters of early arthritis activity were sig-
nificantly higher in IFN-γ-/- mice (AI = 9.4 ± 0.5) com-
pared with their IFN-γ sufficient wild-type (AI = 4.6 ±
0.5) counterparts (Figure 5A). The leukocytes recruited
to the inflamed joint during this phase provide a cellular
source for one of the most prominent catabolic factors
that compromises cartilage integrity, the pro-inflamma-
tory cytokine IL-1 [20]. We found negligible IL-1β stain-
ing in the synovial tissues from WT mice on Day 3
(Figure 5B). In contrast, IFN-γ-/- mice exhibited strong
expression of IL-1β immuno-reactivity both in the
patches of infiltrating cells and in the inflamed synovial
lining layer, most particularly in the pannus adjacent to
areas of cartilage damage (Figure 5C). We did not observe
any chondrocyte-associated IL-1β expression in WT or
IFN-γ-/- mice at any of the time points studied. Control
Figure 4 Development and progression of early arthritis in IFN-γ 
deficient mice. Mono-articular antigen-induced arthritis (AIA) was 
triggered in mice previously immunized against methylated bovine 
serum albumin (mBSA); arthritis was induced after an intra-articular 
(i.a.) injection of mBSA. Plasma and synovial cytokine expression was 
assessed together with histological measures of arthritis severity dur-
ing early arthritis (one day after i.a. mBSA injection). (A) Plasma cy-
tokine expression (mean ± SEM; pg/ml) shown in wild-type and IFN-γ-
/- mice one day after AIA induction; *P < 0.05. (B) and (C), representa-
tive immunohistochemical staining for IL-1β in joint sections from IFN-
γ+/+ and IFN-γ-/- mice respectively; intense positive brown staining 
(denoted by black block arrows) present in the synovial lining layer, 
joint exudate and focal areas of inflamed synovium, (original magnifi-
cation ×10). Arthritis severity was graded in histological sections from 
IFN-γ+/+ (n = 7) and age matched IFN-γ-/- (n = 6) mice one day post 
arthritis induction. (D). Individual parameters of arthritis severity (mean 
± SEM) reported. (E). Representative H&E stained para-sagittal section 
demonstrating histopathology of a IFN-γ+/+ knee joint processed one 
day post arthritis induction. (F). Corresponding section from IFN-γ-/-, 
showing comparable cellular infiltration, synovial hyperplasia and joint 
exudate (original magnification ×4). (G) and (H). Representative, Safra-
nin-O/Fast green stained, para-sagittal section demonstrating typical 
cartilage architecture in arthritic knees on Day 1. Replete GAG staining 
(red) in articular cartilage; (G) IFN-γ+/+ and (H) IFN-γ-/- (original mag-
nification ×20).
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runs, non-specific staining was never detected (data not
shown).
Finally, we questioned whether IFN-γ ablation precipi-
tated cartilage injury during early inflammatory arthritis.
AIA of three-day duration was sufficient to trigger wide-
spread articular damage (visualised by diminished Safra-
nin-O staining) in the articular cartilage of IFN-γ-/- mice
(Figure 5D, E). Examination of joints from WT mice
revealed almost normal structural integrity (Figure 5F).
Discussion
It is likely that the net effect of IFN-γ in vivo is reliant
upon the context in which it is presented; cell/cytokine
milieu, site of action and disease. We used a series of in
vitro and in vivo approaches to demonstrate that IFN-γ
potently protected articular cartilage from inflammation-
induced degradation. Studies outlined herein reveal a
close link between IFN-γ and the control of IL-1β-
induced articular cartilage damage during a critical phase
in the aetiopathogenesis of inflammatory arthritis. Our
findings highlight a potentially important disease-modi-
fying functionality for IFN-γ in early arthritis which
might signify a rethink with regard to timely intervention
with IFN-γ in innovative treatment protocols for inflam-
matory joint diseases such as RA.
To define the manner by which IFN-γ might regulate
catabolic responses induced by IL-1β in humans we util-
ised an in vitro model system using the structural cells
that constitute the inflammatory pannus, namely, FLS
cultured from RA synovial tissue specimens. RA FLS,
which were originally thought to be relatively inert struc-
tural components of the tissue, are now known to play an
important role in regulating tissue homeostasis in healthy
and diseased joints [27,28]. Our observations confirm IL-
1β as a potent activator of MMP-1 and MMP-3 produc-
tion by FLS. However co-incubation with IFN-γ, which
does not itself induce MMP-1 or MMP-3, significantly
reduced IL-1-induced MMP-1 and MMP-3 production.
MMP-1 and MMP-3 are abundant in human RA tissues,
sera and synovial fluids and may be indicative of poor
prognosis and progressive destructive disease [21,29-31].
Our data suggest an important role for IFN-γ in regulat-
ing MMP production by RA FLS. IFN-γ is thus capable of
modulating one of the most important processes driving
tissue degeneration in arthritis.
The mechanism by which IFN-γ regulates IL-1β-
induced MMP production by RA FLS is not known. It
remains to be seen whether IFN-γ modulates RA FLS
responsiveness to IL-1β by modulating cellular expres-
sion of IL-1 receptor and/or IL-1 receptor antagonist (IL-
1RA) and/or regulating signal transducer and activator of
transcription dependent signalling through nuclear factor
κB.
Figure 5 IFN-γ protects the synovial joint from degenerative ar-
ticular changes in early experimental arthritis. Mono-articular anti-
gen-induced arthritis (AIA) was triggered in mice previously 
immunized against methylated bovine serum albumin (mBSA); arthri-
tis was induced after an intra-articular (i.a.) injection of mBSA. Changes 
in joint architecture were measured histologically in joint tissue sec-
tions from IFN-γ+/+ (n = 8) and age matched IFN-γ-/- (n = 10) three 
days after AIA induction. (A). Individual parameters of arthritis severity 
were determined from H&E stained arthritic knee joints; (mean ± SEM) 
reported; *P < 0.01. IL-1β expression was visualised in arthritic joints ex-
cised three days post AIA induction using cytokine specific immuno-
histochemistry. (B) and (C). Representative paraffin wax sections from 
IFN-γ+/+ and IFN-γ-/- stained for IL-1β (original magnification ×40). 
Negligible IL-1β staining observed in synovial tissues from IFN-γ+/+ 
mice (B). In IFN-γ-/- mice (C) intense IL-1β staining often seen in the 
pannus (denoted by red block arrows); articular cartilage frequently 
found damaged with surface fibrillation and clefts extending into tran-
sitional zone (denoted by black block arrows). Serial sections were 
stained with Safranin-O/Fast green. Cartilage depth and the depth of 
GAG depletion were calculated for each mouse from an average of five 
fields per femoral head. (D). Mean ± SEM depths in μm reported for 
IFN-γ+/+ and IFN-γ-/- (*P < 0.01). (E). Representative Safranin-O/Fast 
green stained para-sagittal section from IFN-γ-/- demonstrating severe 
GAG depletion (block arrows) and reduced cellularity. (F). Correspond-
ing section from a IFN-γ+/+ knee joint, minimal GAG depletion ob-
served in the cartilage on the articular surfaces (original magnification 
×20).
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driven by MMPs but their capacity to alter tissue archi-
tecture is tightly regulated by their endogenous inhibi-
tors; the TIMP family [32]. We observed that treatment
of FLS with IL-1β caused significant induction of TIMP-
1. Co-administration of IFN-γ, however, had no signifi-
cant modulating effect. The relationship between ele-
vated TIMP-1 levels in RA patients and radiographic
progression is not entirely clear. A recent study demon-
strated that serum TIMP-1 levels were significantly
higher in patients with progressive RA over those who
had radiographically stable disease [19]. These findings
differed from previous studies, in which no association
was observed between TIMP-1 levels and radiographic
outcome [13,33,34]. In the context of our in vitro studies
MMP-1, MMP-3 and TIMP-1 levels were elevated in
response to IL-1β treatment. Since both destructive and
protective enzymes were induced, it is conceivable that
the ratio of MMP:TIMP should be considered as an indi-
cator of activity when predicting outcome in terms of
IFN-γ's regulatory potential. To explore this we used a
BACE/RA FLS co-culture model to test whether the bal-
ance of enzymes and inhibitors induced by co-adminis-
tration IL-1β with IFN-γ was sufficient to shield cartilage
from IL-1β induced damage. An average MMP-3:TIMP-1
ratio of 0.65 and MMP-1:TIMP-1 ratio of 0.62 were cal-
culated for RA FLS activated by IL-1β alone. These ratios
were reduced by approximately 50%, to 0.33 and 0.34
respectively, following the co-administration of IFN-γ.
This decrease in MMP:TIMP ratio was sufficient to elicit
a strong net protective effect upon the cartilage explants,
thereby identifying an additional homeostatic role for
IFN-γ in limiting inflammation-induced cartilage dam-
age.
We found that IFN-γ gene ablation made mice more
susceptible to inflammation-induced cartilage injury.
Using an experimental model of early arthritis we discov-
ered that IFN-γ-/- mice exhibited detrimental, often irre-
versible, phenotypic changes in articular cartilage
structure. The extensive GAG depletion and frequent
lesions observed in IFN-γ-/- mice were not seen in WT
animals.
IL-1β is considered to be the principal cartilage-cata-
bolic cytokine in arthritis. In murine AIA, significant and
temporal changes in cytokines (IL-1β, TNFα, IFN-γ, IL-6)
and factors that govern extracellular matrix turnover
(MMP-3, MMP-13, TIMP-1) occur during the acute
phase, Days 1 to 3 after arthritis induction [25,35,36]. In
line with published information, the current data demon-
strate maximal IL-1β expression in the joint on Day 1
which is also when peak IFN-γ levels are detected. By Day
3, IFN-γ-/- mice demonstrated elevated IL-1β expression
levels compared to WT animals in the intimal synovial
lining layer and most particularly in the pannus adjacent
to areas of damaged cartilage. The prolonged expression
of IL-1β within the joint and the sustained activation of
synovial cells by IL-1β in the absence of IFN-γ are likely
to aggravate cartilage damage in AIA.
The precise mechanism by which IFN-γ helps maintain
the structural integrity of the joint is ill-defined but is
undoubtedly multi-factorial. We have previously demon-
strated that IFN-γ elicited potent negative-regulatory
function on neutrophil recruitment in arthritis [7]. These
cells, usually found in abundance in patchy synovial infil-
trates, in patients with very early RA [23,24,37], secrete
tissue degrading proteases. Furthermore, IFN-γ acted
synergistically with IL-1 to stimulate IL-1RA production
and inhibit MMP-3 and MMP-13 release in human chon-
drocytes [38,39]. IFN-γ also inhibits MMP-3 mRNA
expression in IL-1 induced primary human macrophages
[40]. IFN-γ is therefore able to curtail IL-1β induced
MMP production by many cell types implicated in per-
petuating structural damage in arthritis; cellular
responses that could potentially dampen early tissue
destruction and joint damage.
Accumulating data reveal diverse mechanisms by
which IFN-γ antagonizes inflammatory and/or pathologi-
cal pathways [41]. In arthritis, for example, IFN-γ: (i)
inhibits neutrophil trafficking [7], (ii) promotes regula-
tory T-cell function [42], (iii) suppresses Th17 cell expan-
sion [43], thereby attenuating inflammation and
preventing T-cell driven osteoclast activation and bone
erosion [44] and (iv) limits the biological activity of inter-
leukin-18 [45]. Our data provide additional unifying evi-
dence for IFN-γ's protective function in arthritis: IFN-γ
lowered IL-1β-induced MMP production by RA FLS,
altered the MMP/TIMP balance in favour of cartilage
protection ex vivo, modulated synovial IL-1β expression
in AIA and ameliorated early cartilage injury in vivo.
These data advance our understanding of the immuno-
protective function of IFN-γ within the synovial joint and
go some way towards identifying mechanisms by which
IFN-γ regulates a chondro-protective outcome during
early inflammatory arthritis.
Conclusions
IFN-γ was previously advocated as safe and well tolerated
for the treatment of chronic progressive RA and juvenile
chronic arthritis [46,47]. The multicenter, randomized,
double-blind trial by Veys et al [46] found that recombi-
nant IFN-γ proved no more effective than placebo in
patients with chronic progressive RA. However, the man-
agement of RA has changed considerably over the past
decade with recognition that earlier treatment provides
superior outcomes. It is possible that an early interven-
tion with IFN-γ may lead to a different result. If a thera-
peutic window exists for RA, then our studies and those
Page et al. Arthritis Research & Therapy 2010, 12:R49
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Page 9 of 10of other groups support a role for IFN-γ in the biological
armamentarium against RA.
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